TICKERNERD
Menu
PBHPBHHealthcare · Drug Manufacturers - Specialty & Generic

PBH Stock Forecast: Prestige Consumer Healthcare, Inc. Price Predictions for 2026-2027

Last close, 3 Sept 2026
$53
−0.51% on the day

The 7 Wall Street analysts covering Prestige Consumer Healthcare, Inc. hold a median 12-month price target of $70 — +33.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 60 of 100 as at 2 Sept 2026 — in the upper half.

Market cap
$2.5B
Ticker Nerd rank
60 / 100
Median analyst target
$70
Analysts covering
7
Revenue$265.7M+6.5% y/y
Operating income$52.5M
Net income$29.2M
Free cash flow$67.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.6%
1M
+1.2%
YTD
−14.8%
1Y
−21.4%
From 52W high
−25.1%
From 52W low
+15.7%
$45
$70
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PBH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Prestige Consumer Healthcare, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 2 Sept 2026
60 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
99
Value
94
Quality
86
Revisions
67
Issuance
43
Growth
38
Size
33
Accruals
29
Momentum
29

Volatility (99): The share price has been relatively steady.

Momentum (29): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PBH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PBH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$50$60$70$80Oct 25Jan 26Apr 26Jul 26PBHHigh $75Median $70Low $55

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
5 Buy2 Hold0 Sell
Low $55Median $70High $75

The green dot is the last close — the median target sits +33.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 May 2026Canaccord GenuityMaintainsBuy$86 → $72
14 May 2026OppenheimerDowngradePerform—
7 May 2026OppenheimerMaintainsOutperform—
2 Feb 2026JefferiesMaintainsHold—
7 Nov 2025Canaccord GenuityMaintainsBuy—
27 Oct 2025JefferiesMaintainsHold—
21 Oct 2025OppenheimerMaintainsOutperform—
8 Aug 2025Canaccord GenuityMaintainsBuy—
21 Mar 2025RBC CapitalMaintainsSector Perform—
13 Feb 2025OppenheimerMaintainsOutperform—
7 Feb 2025Canaccord GenuityMaintainsBuy—
7 Feb 2025DA DavidsonMaintainsBuy—
11 Nov 2024DA DavidsonMaintainsBuy—
24 Sept 2024JefferiesAssumesHold$70 → $76
28 Aug 2024DA DavidsonMaintainsBuy—
9 Aug 2024Canaccord GenuityMaintainsBuy—
9 Aug 2024DA DavidsonMaintainsBuy—
21 June 2024DA DavidsonUpgradeBuy—
21 May 2024Canaccord GenuityMaintainsBuy—
16 May 2024DA DavidsonMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PBH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PBH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 3 Sept 2026, Prestige Consumer Healthcare, Inc. returned −21.4% against +21.4% for the S&P 500, dividends included.

PBH vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Oct 25Jan 26Apr 26Jul 26PBHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PBH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.1%
Analysts raising
1
Analysts cutting
1
Fundamentals

Prestige Consumer Healthcare, Inc. (PBH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
14.7×

Cheaper than 47% of US stocks

Price / sales
2.3×

Cheaper than 50% of US stocks

Price / book
1.3×

Cheaper than 64% of US stocks

EV / EBITDA
13.6×

Cheaper than 26% of US stocks

Growth & margins
Revenue growth (YoY)
6.5%

Higher than 43% of US stocks

Earnings growth (YoY)
−38.5%

Higher than 13% of US stocks

Gross margin
51.3%

Higher than 64% of US stocks

Operating margin
20.8%

Higher than 80% of US stocks

Net margin
15.6%

Higher than 78% of US stocks

Returns & dividend
Return on equity
9.1%

Higher than 61% of US stocks

Return on assets
4.6%

Higher than 74% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Prestige Consumer Healthcare, Inc. (PBH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Prestige Consumer Healthcare, Inc. has a market value of $2.5B and an enterprise value of $4.4B.

  • Revenue in the twelve months to 30 June 2026: $1.1B. The latest quarter grew 6.5% year on year.

  • Net income over the same four quarters: $172.0M, a 15.6% net margin.

  • Diluted earnings per share, trailing twelve months: $3.57.

  • Free cash flow in the twelve months to 30 June 2026: $235.4M.

  • Prestige Consumer Healthcare, Inc. spent $121.5M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 47.4M.

  • Trailing P/E: 14.7×; forward P/E: 10.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Prestige Consumer Healthcare, Inc. employs 890 people — $1.2M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 1 Sept 2026

Data provided by Twelve Data

Peers

PBH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
PBHPrestige Consumer Healthcare, Inc.$2.5B
60
SUPNSupernus Pharmaceuticals, Inc.$2.5B
81
BCRXBioCryst Pharmaceuticals, Inc.$2.5B
88
BHCBausch Health Cos., Inc.$2.5B
97
TRLVTrulieve Cannabis Corp.$2.2B
88
ALVOAlvotech$2.1B
30
RGCRegencell Bioscience Holdings Ltd.$3.1B
4

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Prestige Consumer Healthcare, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PBH news & analysis

Is This the Right Time to Add PBH Stock to Your Portfolio?

Zacks Investment Research · 2 Sept 2026neutral

Zacks Investment Research published an article examining whether now is the right time to add Prestige Consumer Healthcare (PBH) stock to a portfolio. The piece notes the company benefits from acquisitions, e-commerce growth and strong cash flow, while currency swings and high debt remain key risks.

Why it matters — The article highlights PBH's key growth drivers and risk factors, giving investors a balanced view of the company's current position.

Football Stress May Be Following Fans to Bed, According to the Inaugural DenTek® Football Stress Test

PRNewsWire · 1 Sept 2026neutral

DenTek, the leading OTC dental guard brand for nighttime teeth grinding, released results of a national survey on football-related stress, finding nearly 8 in 10 fans continue thinking about the game after it ends and exhibit stress-related behaviors that extend into bedtime. NFL legends Ronde and Tiki Barber are partnering with the brand to raise awareness about recognizing football stress beyond game day.

Why it matters — This survey highlights a consumer stress driver that could support demand for DenTek's teeth-grinding guard products, a key over-the-counter healthcare line for PBH.

PBH vs. SYK: Which Stock Is the Better Value Option?

Zacks Investment Research · 28 Aug 2026neutral

Zacks Investment Research published a comparison piece examining whether Prestige Consumer Healthcare (PBH) or Stryker (SYK) offers better value for investors in the Medical - Products sector. The article poses the question of which stock is the better value option at this time.

Why it matters — The piece highlights how PBH is being evaluated alongside a major peer by investment analysts, giving PBH watchers a sense of where the stock stands in value-focused comparisons.

Here's Why Prestige Consumer Healthcare (PBH) is a Strong Value Stock

Zacks Investment Research · 14 Aug 2026positive

Zacks Investment Research reports that Prestige Consumer Healthcare (PBH) is a strong value stock per its Style Scores, which are presented as a way to identify strong, market-beating stocks for an investment portfolio. The item highlights PBH's value characteristics without providing specific figures.

Why it matters — This item signals to PBH watchers that the company is being flagged by Zacks' Style Scores as a strong value stock, an external assessment of its investment profile.

PBH or SYK: Which Is the Better Value Stock Right Now?

Zacks Investment Research · 12 Aug 2026neutral

A Zacks Investment Research article compares Prestige Consumer Healthcare (PBH) and Stryker (SYK) as value stock opportunities in the Medical - Products sector.

Why it matters — The article frames PBH as being evaluated against a major competitor for value-investing appeal, which could influence how investors perceive PBH relative to peers.

FAQ

Frequently asked questions about PBH stock

What is the PBH stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Prestige Consumer Healthcare, Inc. have a median 12-month price target of $70, with estimates ranging from $55 to $75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PBH stock a buy right now?

Of the 7 analysts covering Prestige Consumer Healthcare, Inc., 5 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Prestige Consumer Healthcare, Inc. 60 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PBH?

As at 2 Sept 2026, Prestige Consumer Healthcare, Inc. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).

Will PBH stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +33.2% from the last close, and Ticker Nerd's factor model ranks Prestige Consumer Healthcare, Inc. 60 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PBH stock forecast for 2030?

No analyst covering Prestige Consumer Healthcare, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PBH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $55 to $75 over the next 12 months.

How has PBH stock performed over the past year?

Prestige Consumer Healthcare, Inc. returned -21.4% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Prestige Consumer Healthcare, Inc. do?

Prestige Consumer Healthcare Inc. is a consumer healthcare company that develops, manufactures, markets, distributes, and sells branded over-the-counter health and personal care products.

What is the latest news on PBH?

The most recent item we track (Zacks Investment Research, 2 Sept 2026): "Is This the Right Time to Add PBH Stock to Your Portfolio?". Zacks Investment Research published an article examining whether now is the right time to add Prestige Consumer Healthcare (PBH) stock to a portfolio. The piece notes the company benefits from acquisitions, e-commerce growth and strong cash flow, while currency swings and high debt remain key risks.

Company

About Prestige Consumer Healthcare, Inc.

Prestige Consumer Healthcare Inc. is a consumer healthcare company that develops, manufactures, markets, distributes, and sells branded over-the-counter health and personal care products. Prestige Consumer Healthcare Inc. focuses on everyday self-care categories such as pain relief, sore throat care, eye care, digestive health, skin protection, diaper rash treatment, ear wax removal, women’s care, and oral care. Its portfolio includes well-known products sold through mass merchandisers, drugstores, grocery retailers, dollar stores, convenience channels, club stores, and e-commerce outlets across North America, Australia, and other international markets. The company operates through North American OTC Healthcare and International OTC Healthcare segments, giving it broad exposure to consumer wellness products used for common, recurring health needs. Prestige Consumer Healthcare Inc. plays a specialized role in the market as a branded over-the-counter healthcare provider with a portfolio centered on established consumer brands.

CEO Mr. Ronald M. Lombardi C.P.A. · 890 employees · United States · https://www.prestigebrands.com